90Y ibritumomab tiuxetan (Y2B8, Zevalin®) radioimmunotherap (RIT) is highly effective for relapsed or refractory indolent B-cell non-Hodgkin's lyrnphoma (B-NHL) pretreated with rituximab-containing chemotherapy (R-chemo):: Japanese multicenter phase II study.

被引：5
|
作者：
Ogura, Michinori
Morishima, Yasuo
Watanabe, Takashi
Hotta, Tomomitsu
Ishizawa, Kennichi
Itoh, Kuniaki
Okamoto, Shinichiro
Taniwaki, Masafumi
Endo, Kengo
Tobinai, Kensei
机构：
[1] Aichi Canc Ctr Hosp, Dept Hematol & Cell Therapy, Nagoya, Aichi 464, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Tokai Univ, Sch Med, Isehara, Kanagawa 25911, Japan
[4] Tohoku Univ, Sch Med, Sendai, Miyagi 980, Japan
[5] Natl Canc Ctr Hosp E, Kashiwa, Chiba, Japan
[6] Keio Univ, Sch Med, Tokyo, Japan
[7] Kyoto Prefectural Univ, Kyoto 606, Japan
[8] Gunma Univ Hosp, Maebashi, Gumma, Japan
[9] Nagoya Daini Red Cross Hosp, Nagoya, Aichi, Japan
[10] Nagoya Med Ctr, Nagoya, Aichi, Japan
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2767.2767
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2767
引用
收藏
页码：783A / 784A
页数：2
相关论文
共 36 条
  • [1] Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
    Tobinai, Kensei
    Watanabe, Takashi
    Ogura, Michinori
    Morishima, Yasuo
    Hotta, Tomomitsu
    Ishizawa, Kenichi
    Itoh, Kuniaki
    Okamoto, Shin-ichiro
    Taniwaki, Masafumi
    Tsukamoto, Norifumi
    Okumura, Hirokazu
    Terauchi, Takashi
    Nawano, Shigeru
    Matsusako, Masaki
    Matsuno, Yoshihiro
    Nakamura, Shigeo
    Mori, Shigeo
    Ohashi, Yasuo
    Hayashi, Masaki
    Endo, Keigo
    CANCER SCIENCE, 2009, 100 (01) : 158 - 164
  • [2] Bendamustine Is Highly Effective for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mantle Cell Lymphoma (MCL): Final Results of a Japanese Multicenter Phase II Study.
    Ogura, Michinori
    Uchida, Toshiki
    Ando, Kiyoshi
    Ohmachi, Ken
    Itoh, Kuniaki
    Kubota, Nobuko
    Ishizawa, Kenichi
    Yamamoto, Joji
    Watanabe, Takashi
    Uike, Naokuni
    Choi, Ilseung
    Terui, Yasuhito
    Usuki, Kensuke
    Nagai, Hirokazu
    Uoshima, Nobuhiko
    Tobinai, Kensei
    BLOOD, 2009, 114 (22) : 1422 - 1422
  • [3] Evaluation of baseline body-weight dosing of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Wiseman, G
    Conti, P
    Vo, K
    Schilder, RJ
    Foster, P
    Gordon, LI
    Emmanouilides, C
    Silverman, D
    Witzig, TE
    Molina, A
    BLOOD, 2004, 104 (11) : 721A - 721A
  • [4] 90Y ibritumomab tiuxetan and rituximab for the treatment of relapsed or refractor), diffuse large B-cell non-Hodgkin's lymphoma.
    Buff, Michael S.
    Royer, Anna
    Ely, Pamela
    Grant, Barbara
    Parker, J. Anthony
    Joyce, Robin M.
    BLOOD, 2006, 108 (11) : 779A - 779A
  • [5] Yttriutm-90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Wiseman, GA
    Witzig, TE
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (02) : 185 - 188
  • [6] Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)
    Swinnen, L. J.
    Flinn, I. W.
    Kahl, B. S.
    Frey, E.
    Rogers, K.
    Jung, M.
    Jacene, H.
    Wahl, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
    Wiseman, GA
    White, CA
    Stabin, M
    Dunn, WL
    Erwin, W
    Dahlbom, M
    Raubitschek, A
    Karvelis, K
    Schultheiss, T
    Witzig, TE
    Belanger, R
    Spies, S
    Silverman, DHS
    Berlfein, JR
    Ding, E
    Grillo-Lópezs, AJ
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (07) : 766 - 777
  • [8] Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma
    Gregory A. Wiseman
    Christine A. White
    Michael Stabin
    William L. Dunn
    William Erwin
    Magnus Dahlbom
    Andrew Raubitschek
    Kastytis Karvelis
    Timothy Schultheiss
    Thomas E. Witzig
    Richard Belanger
    Stewart Spies
    Daniel H. S. Silverman
    Judy R. Berlfein
    Eric Ding
    Antonio J. Grillo-López
    European Journal of Nuclear Medicine, 2000, 27 : 766 - 777
  • [9] A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL).
    Ando, Kiyoshi
    Ogura, Michinori
    Suzuki, Tatsuya
    Ishizawa, Kenichi
    Oh, Sung Yong
    Kim, Won Seog
    Tanaka, Yoshinobu
    Shimamoto, Takashi
    Tobinai, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] 90Y-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin s Lyniphoma
    Luptakova, Katarina
    Kim, Michelle
    Ely, Pamela
    Grant, Barbara
    Parker, John Anthony
    Tzachanis, Dimitrios
    Rosenblatt, Jacalyn
    Levine, James
    Avigan, David
    Joyce, Robin
    BLOOD, 2010, 116 (21) : 1180 - 1180
1234